Predictive Oncology – Year-end Shareholder Update!
December 21 2021 - 8:30AM
Predictive Oncology, (POAI), a knowledge-driven company focused on
applying artificial intelligence (AI) to develop personalized
cancer therapies, is moving in the right direction.
In November 2021, POAI acquired zPREDICTA, a cutting edge cancer
based company with a proven commercial and scientific record. Their
patented 3D cell culture platform has already been proven
successful. zPREDICTA’s technology has been validated in Multiple
Myeloma and cell growth. We believe, this is the only human bone
marrow-derived cell culture model capable of maintaining primary
multiple myeloma cells. The science is now being adapted to
other cancer cell cultures.
Besides the synergies already present with our Helomics and
TumorGenesis divisions, the acquisition provides a foot in the door
for POAI to large pharmaceutical customers already doing business
with zPREDICTA. We now possess a “one-two” punch to pharma with the
established 3D cell culture platform and our CoRE™ artificial
intelligent technology that will cut costs and time in drug
discovery and drug repurposing.
zPREDICTA brings a historical revenue stream and profitable
bottom-line to POAI. Coupled with our anticipated commercialization
of our Discovery 21 project, POAI is emerging from a research and
development-only company to a biopharmaceutical revenue-based
company.
To support our commercialization efforts, POAI announced the
hiring of Pamela Bush, Ph.D, MBA, on December 7, 2021. Dr. Bush
will lead our sales and business development initiatives, while
integrating our sales and marketing efforts throughout the
Company.
Predictive Oncology has four interwoven divisions: Helomics,
TumorGenesis, Soluble Biotech and, now, zPREDICTA. Our legacy
company, Skyline Medical, continues to sell the STREAMWAY System®,
producing revenue and covering its own cost, while we consider
options for selling the division.
Working together, we endeavor to eliminate cancer while
simultaneously providing strong returns to our investors.
Thank you,
J. Melville (“Mel”) Engle
About Predictive Oncology
Predictive Oncology Inc. (NASDAQ: POAI) is a knowledge-driven
company focused on applying artificial intelligence (AI) to develop
personalized cancer therapies, which can lead to more effective
treatments and improved patient outcomes. Using artificial
intelligence, Predictive Oncology uses a database of 150,000+
cancer tumors, categorized by patient type, against drug compounds
to determine optimal therapies to be used to ultimately eliminate
cancer.
As the drug discovery community has now realized, a
genomics-based approach to cancer research and drug development is
insufficient to achieve the promise of personalized therapeutics.
Predictive Oncology instead takes a multiomic approach, which
considers the vast multitude of factors that make each cancer
unique.
Forward-Looking Statements: Certain matters discussed in this
release contain forward-looking statements. These forward-looking
statements reflect our current expectations and projections about
future events and are subject to substantial risks, uncertainties
and assumptions about our operations and the investments we make.
All statements, other than statements of historical facts, included
in this press release regarding our strategy, future operations,
future financial position, future revenue and financial
performance, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,”
“target” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Our actual future
performance may materially differ from that contemplated by the
forward-looking statements as a result of a variety of factors
including, among other things, risks related to the acquisition of
zPREDICTA including no assurance of future operating results of
zPREDICTA, no assurance that zPREDICTA’s customers will continue to
utilize zPREDICTA’s services at historical levels or at all, risk
of higher than anticipated expenses, integration risk, risk of
future impairment of goodwill that would impact POAI’s operating
results and reliance on zPREDICTA’s management and employees, and
the factors discussed under the heading “Risk Factors” in our
filings with the SEC. Except as expressly required by law, the
Company disclaims any intent or obligation to update these
forward-looking statements
Investor Relations Contact:Landon Capital Keith Pinder (404)
995-6671kpinder@landoncapital.net
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Sep 2023 to Sep 2024